By Himiyer.com — March 23, 2026
What the FDA Released
On January 23, 2026, the FDA published its 2026 deliverables for the Human Foods Program (HFP), a document that functions as the agency's public commitment list for the year — outlining what actions, guidances, and rulemakings the FDA's Office of Dietary Supplement Programs (ODSP) and other food divisions intend to complete or advance. These deliverables carry weight because they set expectations for industry compliance teams, policy advocates, and investors tracking regulatory risk.
Key Supplement Priorities
Three supplement-specific items are prominently listed in the 2026 deliverables. First, the FDA intends to pursue reform of the self-affirmed GRAS pathway, potentially requiring companies to notify the agency before any new substance enters the food and supplement supply. Second, the agency committed to providing updated guidance on New Dietary Ingredient (NDI) safety and identity standards — a long-sought clarification for manufacturers of novel ingredients. Third, the ODSP listed broader modernization of the DSHEA regulatory framework as a priority, particularly around the drug preclusion clause that caused three years of legal dispute over NMN.
What Was Excluded
Notably absent from the FDA's 2026 deliverables is any commitment to mandatory product listing — the requirement that manufacturers register every supplement with the agency. That item, central to Sen. Durbin's Dietary Supplement Listing Act of 2026, would require congressional action rather than agency rulemaking alone, explaining its absence from FDA's internal deliverables list. Industry groups that have opposed mandatory listing took the exclusion as a modest win.
Industry Reaction
Reactions from the supplement industry have been mixed. Larger trade groups broadly welcomed the modernization agenda, particularly any movement on the drug preclusion clause. Smaller and growth-stage companies expressed concern that tighter NDI standards combined with mandatory GRAS notification could slow the pipeline of new ingredients, particularly those derived from precision fermentation or cell culture — areas where the FDA's upcoming public meeting will shed more light.
